NasdaqGS:ALNY

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. More Details


Snowflake Analysis

Excellent balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Alnylam Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALNY's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-6.5%

ALNY

-2.5%

US Biotechs

-4.1%

US Market


1 Year Return

35.5%

ALNY

25.0%

US Biotechs

12.0%

US Market

Return vs Industry: ALNY exceeded the US Biotechs industry which returned 25% over the past year.

Return vs Market: ALNY exceeded the US Market which returned 12% over the past year.


Shareholder returns

ALNYIndustryMarket
7 Day-6.5%-2.5%-4.1%
30 Day-15.3%-2.1%-0.2%
90 Day-15.4%-1.8%2.8%
1 Year35.5%35.5%27.1%25.0%14.6%12.0%
3 Year-6.8%-6.8%18.0%12.0%35.8%26.8%
5 Year21.5%21.5%8.9%1.0%75.2%55.6%

Price Volatility Vs. Market

How volatile is Alnylam Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Alnylam Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ALNY ($123.32) is trading below our estimate of fair value ($478.01)

Significantly Below Fair Value: ALNY is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ALNY is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ALNY is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALNY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALNY is overvalued based on its PB Ratio (10.2x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Alnylam Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?

63.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALNY is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALNY is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALNY is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALNY's revenue (43.8% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: ALNY's revenue (43.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ALNY is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Alnylam Pharmaceuticals performed over the past 5 years?

-26.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALNY is currently unprofitable.

Growing Profit Margin: ALNY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALNY is unprofitable, and losses have increased over the past 5 years at a rate of 26.5% per year.

Accelerating Growth: Unable to compare ALNY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALNY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.8%).


Return on Equity

High ROE: ALNY has a negative Return on Equity (-60.45%), as it is currently unprofitable.


Next Steps

Financial Health

How is Alnylam Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: ALNY's short term assets ($2.2B) exceed its short term liabilities ($384.3M).

Long Term Liabilities: ALNY's short term assets ($2.2B) exceed its long term liabilities ($1.6B).


Debt to Equity History and Analysis

Debt Level: ALNY is debt free.

Reducing Debt: ALNY had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALNY has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ALNY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Alnylam Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALNY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALNY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALNY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALNY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALNY's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

John Maraganore (57 yo)

17.83yrs

Tenure

US$7,317,856

Compensation

Dr. John M. Maraganore, M.D., Ph.D. was an Advisor at Flex Pharma, Inc. Dr. Maraganore has been the Chief Executive Officer and Executive Director at Alnylam Pharmaceuticals, Inc. since December 2002. He h ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD7.32M) is below average for companies of similar size in the US market ($USD11.21M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
John Maraganore
CEO & Executive Director17.83yrsUS$7.32m0.17%
$ 24.8m
Yvonne Greenstreet
President & COOno dataUS$3.25m0.0045%
$ 645.0k
Jeffrey Poulton
Chief Financial Officer1.17yrsUS$6.16m0.000050%
$ 7.2k
Akshay Vaishnaw
President of Research & Development11.83yrsUS$3.10m0.013%
$ 1.8m
Alfred Boyle
Senior Vice President of Technical Operationsno datano datano data
Kevin Fitzgerald
Senior VP & Chief Scientific Officer1.42yrsno datano data
Christine Lindenboom
Senior VP of Investor Relations & Corporate Communicationsno datano datano data
Laurie Keating
Executive VP6.08yrsUS$5.31m0.0029%
$ 421.9k
Nereyda Garcia
Global Head of Ethics & Compliance4.75yrsno datano data
Mark Baglin
Vice President of Global Marketing3.75yrsno datano data
Kelley Boucher
Chief Human Resource Officer1.42yrsno datano data
Muthiah Manoharan
Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board5yrsno datano data

4.3yrs

Average Tenure

57yo

Average Age

Experienced Management: ALNY's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
John Maraganore
CEO & Executive Director17.83yrsUS$7.32m0.17%
$ 24.8m
Muthiah Manoharan
Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board5yrsno datano data
Michael Bonney
Independent Chairman4.83yrsUS$505.71k0.0034%
$ 493.4k
Paul Schimmel
Member of the Scientific Advisory Boardno dataUS$475.71k0.26%
$ 37.9m
David E. Pyott
Independent Director4.83yrsUS$470.71k0.024%
$ 3.4m
Phillip Sharp
Co-Founder18.33yrsUS$495.71k0.23%
$ 32.9m
Marsha Fanucci
Independent Director9.83yrsUS$490.71k0%
$ 0
Amy Schulman
Independent Director6.25yrsUS$485.71k0%
$ 0
Markus Stoffel
Member of Scientific Advisory Boardno datano datano data
David Bartel
Member of Scientific Advisory Boardno datano datano data
Dennis Ausiello
Member of the Scientific Advisory Board & Independent Director8.5yrsUS$470.71k0.0030%
$ 431.9k
Rachel Meyers
Member of Scientific Advisory Boardno datano datano data

7.4yrs

Average Tenure

67yo

Average Age

Experienced Board: ALNY's board of directors are considered experienced (7.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.3%.


Top Shareholders

Company Information

Alnylam Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Alnylam Pharmaceuticals, Inc.
  • Ticker: ALNY
  • Exchange: NasdaqGS
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$14.301b
  • Shares outstanding: 115.97m
  • Website: https://www.alnylam.com

Number of Employees


Location

  • Alnylam Pharmaceuticals, Inc.
  • 675 West Kendall Street
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALNYNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2004
DULDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2004
DULXTRA (XETRA Trading Platform)YesCommon StockDEEURMay 2004
0HD2LSE (London Stock Exchange)YesCommon StockGBUSDMay 2004
ALNY *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNMay 2004
A1LN34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 20 REPR 1 COM NPVBRBRLOct 2020

Biography

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company’s pipeline of investigational RNAi ther ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/30 03:52
End of Day Share Price2020/10/29 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.